RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Presents at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
October 12, 2021 10:47 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Receives Notice of Allowance for New U.S. Patent Covering kt-2000 series PARP Inhibitors
October 07, 2021 09:00 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSX-V: RKV) today announced that the Company has received notice of allowance from the...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Presents Preclinical Data on novel kt-3000 Series Drug Candidates at JCA-AACR Precision Medicine International Conference
September 16, 2021 09:00 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics to Present at the JCA-AACR Precision Medicine International Conference
September 09, 2021 12:49 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 26, 2021 09:00 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company committed to advancing new cancer therapies based on novel...